Related Experiment Video

Updated: Aug 14, 2026

Spheroid Assay to Measure TGF-β-induced Invasion
09:18

Spheroid Assay to Measure TGF-β-induced Invasion

Published on: November 16, 2011

Defects of TGF-beta receptor signaling in mammary cell tumorigenesis

M G Brattain1, Y Ko, S S Banerji

  • 1Department of Biochemistry and Molecular Biology, Medical College of Ohio, Toledo 43699-0008, USA.

Journal of Mammary Gland Biology and Neoplasia
|October 1, 1996
PubMed

Insights

Estrogen receptor-positive breast cancer often resists transforming growth factor beta (TGF-beta) due to inadequate TGF-beta type II receptor (TGFRII) expression. Restoring TGFRII can reverse malignancy, suggesting therapeutic potential.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • Transforming growth factor beta (TGF-beta) plays a crucial role in cell growth and differentiation.
  • Estrogen receptor (ER) status significantly influences TGF-beta signaling in breast cancer.
  • ER-positive (ER+) breast cancer cells typically exhibit resistance to TGF-beta's inhibitory effects.

Purpose of the Study:

  • To review TGF-beta receptor expression and signal transduction in human breast cancer.
  • To investigate the relationship between ER status and TGF-beta sensitivity.
  • To explore mechanisms of TGF-beta resistance in different breast cancer subtypes.

Main Methods:

  • Literature review of studies on TGF-beta receptor expression and signaling in breast cancer.
  • Analysis of TGF-beta sensitivity in relation to ER status (ER+ vs. ER-).
  • Examination of TGFRII expression levels in various breast cancer cell lines.
  • Review of studies involving TGFRII transfection and its effects on TGF-beta sensitivity and malignancy.

Main Results:

  • ER+ breast cancer cells are generally resistant to TGF-beta, with exceptions like early-passage MCF-7 cells.
  • Loss of TGF-beta sensitivity in ER+ cells is often linked to reduced TGF-beta type II receptor (TGFRII) expression.
  • Stable TGFRII transfection in ER+ cells restores TGF-beta sensitivity and reduces malignancy.
  • ER- breast cancer cells usually express TGFRII but show limited TGF-beta sensitivity, indicating post-receptor resistance mechanisms.

Conclusions:

  • TGF-beta receptor expression and signaling are critical in breast cancer progression.
  • TGFRII expression is a key determinant of TGF-beta sensitivity in ER+ breast cancer.
  • ER- breast cancer cells, despite TGFRII expression, offer valuable models to study post-receptor TGF-beta resistance mechanisms.

More Related Videos

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Related Concept Videos

Hedgehog Signaling Pathway02:33

Hedgehog Signaling Pathway

The Hedgehog gene (Hh) was first discovered due to its control of the growth of disorganized, hair-like bristles phenotype in Drosophila, much like hedgehog spines. Hh plays a crucial role in the development of organs and the maintenance of homeostasis in both invertebrates and vertebrates. However, while Drosophila has only one Hh protein, mammals have multiple functional Hedgehog proteins - Sonic (Shh), Desert (Dhh), and Indian Hedgehog (Ihh). All of these homologous proteins have adapted to...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...